CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the
May 15 2008 - 9:00AM
PR Newswire (US)
Blood Pressure Control Doubled with ICG-Guided Therapy On Over
76,000+ Patient Visits SAN DIEGO, May 15 /PRNewswire-FirstCall/ --
CardioDynamics (NASDAQ:CDICD), the innovator and leader of
Impedance Cardiography (ICG) technology and manufacturer of BioZ(R)
noninvasive cardiac monitoring systems, today announced the
presentation of a significant independent ICG clinical study at the
Twenty-third Annual American Society for Hypertension (ASH)
Scientific Meeting in New Orleans, Louisiana. Study results were
reported from a 65 physician primary care and cardiology group
practice and demonstrated an impressive 102% improvement in blood
pressure control rates, with control rates improving from 42% to
88%. Over 76,000 patient visits were included in the analysis.
Robert E. Matthews, Executive Director, PriMed Physicians, Dayton
Ohio, stated, "Our physician group has set strategic goals to
achieve nationally recognized levels of clinical and service
quality, particularly chronic disease management including
hypertension. We used a Six Sigma quality approach to develop a
process for the treatment of patients diagnosed with hypertension
and we incorporated the use of BioZ ICG to guide antihypertensive
therapy selection in patients whose blood pressure was not at goal.
Our analysis clearly and repeatedly showed that the use of ICG was
a significant contributor to whether or not the patient achieved
goal blood pressure and allowed us to achieve the highest known
hypertension control rate of all group practices in the United
States." Douglas Magenheim, M.D., M.B.A, Medical Director for
PriMed, initially piloted use of the BioZ ICG and found that it
significantly improved his ability to help achieve appropriate
hypertension control. Based upon his experience, the group
initially included BioZ ICG in the Hypertension quality process and
measured whether, in fact, it would be an effective, value added
step in changing outcomes. Mark Couch, M.D., President, PriMed
Physicians, stated, "According to JNC-7 national guidelines and
several other studies, approximately 31% to 34% of patients who
have the diagnosis of hypertension are actually achieving goal
blood pressure. Our group's baseline, pre-intervention results
demonstrated that 42% of our patients were at or better than the
JNC-7 goal blood pressures. This rate, while better than the
national average, left great room for improvement. We are extremely
pleased with the 88% control rates we have achieved and the fact
that we appear to lead the nation in managing this very highly
important disease. Our internal Six Sigma studies have repeatedly
confirmed that the use of ICG was a significant tool to assist our
physicians and patients to achieve blood pressure goal. Conversely,
the achievement of goal blood pressure was significantly impeded
when this test was not used on hypertensive patients. Therefore, we
have adopted a policy as a group that our physicians shall use the
Hypertension Process, including ICG, when the patient's blood
pressure is not at goal." Multiple classes of antihypertensive
medications have been identified, and more than 100 medications are
available for the treatment of high blood pressure. However,
improved blood pressure control has remained an elusive target
despite great public and physician awareness and a large armament
of antihypertensive medications with proven benefit. The number of
available drugs and co-morbidities creates difficult blood pressure
management decisions, especially in the patient with long-standing
hypertension. ICG has emerged as a valuable new tool for diagnostic
and prognostic assessment in hypertensive patients to aid
therapeutic decision making. "These are impressive, real-world
results, nearly three times the national average, across a 65-plus
multi-specialty physician group practice," stated Michael K. Perry,
CardioDynamics' Chief Executive Officer. "The medical community
continues to validate ICG's usefulness in physicians' diagnosis and
treatment as well as patient outcomes. We remain committed to
partnering with the research community to incorporate ICG into the
treatment guidelines and to significantly improve outcomes for the
millions of patients with high blood pressure, heart failure and
other forms of cardiovascular disease." About CardioDynamics
CardioDynamics (NASDAQ:CDICD), the ICG Company, is the innovator
and leader of an important medical technology called impedance
cardiography (ICG). The Company develops, manufactures and markets
noninvasive ICG diagnostic and monitoring devices and markets
proprietary ICG sensors. The Company's ICG Systems are being used
by physicians around the world to help battle the number one killer
of men and women -- cardiovascular disease. Partners include GE
Healthcare, Philips Medical Systems and Mindray. For additional
information, please refer to the company's Web site at
http://www.cdic.com/. Forward-Looking (Safe Harbor) Statement
Except for historical and factual information contained herein,
this press release contains forward-looking statements the accuracy
of which is necessarily subject to uncertainties and risks
including the Company's sole dependence on the BioZ product line,
and various uncertainties characteristic of early growth companies,
as well as other risks detailed in the Company's filings with the
SEC, including its 2007 Form 10-K. The Company does not undertake
to update the disclosures contained in this press release.
DATASOURCE: CardioDynamics CONTACT: Rhonda F. Rhyne of
CardioDynamics, 1-800-778-4825, Ext. 1013, Web site:
http://www.cdic.com/
Copyright
Cardiodynamics International (MM) (NASDAQ:CDICD)
Historical Stock Chart
From Apr 2024 to May 2024
Cardiodynamics International (MM) (NASDAQ:CDICD)
Historical Stock Chart
From May 2023 to May 2024